Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01333
|
|||||
| Drug Name |
Boceprevir
|
|||||
| Synonyms |
(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide; 3-{[(1R,2S,5S)-3-[(2S)-2-[(tert-butylcarbamoyl)amino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2-yl]formamido}-4-cyclobutyl-2-oxobutanamide; 394730-60-0; 89BT58KELH; Boceprevir; CHEBI:68621; EBP 520; SCH 503034; SCH-503034; UNII-89BT58KELH; Victrelis
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Hepatitis C virus infection [ICD11: 1E50.2, 1E51.1] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C27H45N5O5
|
|||||
| Canonical SMILES |
CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C
|
|||||
| InChI |
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
|
|||||
| InChIKey |
LHHCSNFAOIFYRV-DOVBMPENSA-N
|
|||||
| CAS Number |
CAS 394730-60-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 519.7 | Topological Polar Surface Area | 151 | ||
| Heavy Atom Count | 37 | Rotatable Bond Count | 10 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.1
|
|||||
| PubChem CID | ||||||
| PubChem SID |
15333889
, 22433429
, 22693607
, 41390184
, 46512784
, 57374555
, 57414843
, 79603721
, 92309409
, 96025559
, 103500897
, 109692987
, 134348397
, 135216213
, 137186019
, 137251857
, 139040316
, 152258143
, 160645839
, 160646982
, 162256796
, 163667336
, 164837112
, 175427026
, 175427127
, 176245990
, 180371765
, 198992422
, 223366205
, 223669397
, 226940314
, 245972903
, 249582863
, 251970943
, 252076908
|
|||||
| ChEBI ID |
CHEBI:68621
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Boceprevir was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Drug interactions and protease inhibitors used in the treatment of hepatitis C: how to manage? Eur J Clin Pharmacol. 2014 Jul;70(7):775-89. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.